# US 2019/0314425 A1 · Akkermansia muciniphila strain having a prophylactic or therapeutic effect on a degenerative brain disease or metabolic disease and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314425 A1
- Document ID: US20190314425A1
- Status: Published application
- Kind: A1
- Application number: 16/316,796
- Filed: 2017-07-11
- Published: 2019-10-17
- Earliest claimed: 2016-07-11
- Applicants: Korea Research Institute of Bioscience and Biotechnology
- Inventors: Byoung-Chan KIM; Chul-Ho LEE; Jung-Ran NOH; Kyoung-Shim KIM; Myung-Hee KIM; Yong-Hoon KIM; Sang Jun LEE; Dong-Ho CHANG; Dong-Hee CHOI; Jung Hwan HWANG; Yun-Jung SEO; In-Bok LEE; Young-Keun CHOI; Jung-Hyeon CHOI
- Web page: https://patentgrep.com/patent/US20190314425A1

## CPC

- A23K 10/18: of live microorganisms
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A23K 10/16: Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions (A23K10/12 takes precedence)
- A23K 50/50: for rodents
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 1/20: Bacteria; Culture media therefor
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A23V 2200/322: having an effect on the health of the nervous system or on mental function
- C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales}
- A23K: FODDER
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

The present disclosure relates to an Akkermansia muciniphila strain having a prophylactic or therapeutic effect on a degenerative brain disease and uses thereof. Since the Akkermansia muciniphila strain, the intestinal microorganism of the present disclosure, shows an effect of improving movement control and cognitive abilities as well as memory in an animal model having a degenerative brain disease such as Parkinson's disease and Alzheimer's disease, it can be useful in the prevention or treatment of brain diseases including Alzheimer's disease, Parkinson's disease, mild cognitive impairment, etc. In addition, it was confirmed in the present disclosure that compared to the Akkermansia muciniphila strain cultured in a mucin-containing medium, that cultured in a mucin-free medium showed a remarkable effect of improving hyperlipidemia, fatty liver, obesity, and hyperglycemia induced in a mouse model by high-fat diet when administered orally (in vivo). Accordingly, the present disclosure is expected to be very useful in relevant industries as a particular composition of culture medium and an optimized obligatory anaerobic culture method have been developed through the present disclosure.

## Claims

### Claim 1

An Akkermansia muciniphila strain having a prophylactic or therapeutic effect on a degenerative brain disease.

### Claim 2 (depends on 1)

A method of preventing or treating a degenerative brain disease, comprising a step of:
administering a pharmaceutical composition comprising as an active ingredient at least one selected from the group consisting of the strain according to claim 1, an endoplasmic reticulum derived therefrom, a culture thereof, a concentrate of the culture, a dry matter of the culture, and an extract of the culture.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the degenerative brain disease is Alzheimer's disease, Parkinson's disease, mild cognitive impairment, meningitis, stroke, dementia, Huntington's disease, or Creutzfeldt-Jakob disease.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the pharmaceutical composition has an inhibition effect on movement disorders due to dopaminergic neuron death.

### Claim 5 (depends on 2)

The method according to claim 2, wherein the pharmaceutical composition has an inhibition effect on cerebral inflammatory responses.

### Claim 6 (depends on 2)

The method according to claim 2, wherein the pharmaceutical composition has an improvement effect on cognitive ability and memory.

### Claim 7 (depends on 1)

A method of preventing or improving a degenerative brain disease, comprising a step of:
administering a health functional food composition comprising as an active ingredient at least one selected from the group consisting of the strain according to claim 1, an endoplasmic reticulum derived therefrom, a culture thereof, a concentrate of the culture, a dry matter of the culture, and an extract of the culture.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the health functional food composition further comprises in addition to the active ingredient at least one selected from a nutrient, a vitamin, an electrolyte, a flavoring agent, a coloring agent, an enhancer, a pectic acid and a salt thereof, an alginic acid and a salt thereof, an organic acid, a protective colloid thickening agent, a pH-adjusting agent, a stabilizer, a preservative, glycerin, an alcohol, and a carbonating agent used for carbonated drinks.

### Claim 9 (depends on 1)

A method of preventing or improving a degenerative brain disease, comprising a step of:
administering a feed additive composition comprising as an active ingredient at least one selected from the group consisting of the strain according to claim 1, an endoplasmic reticulum derived therefrom, a culture thereof, a concentrate of the culture, a dry matter of the culture, and an extract of the culture.

### Claim 10

A method of preventing or treating a metabolic disease, comprising a step of:
administering a pharmaceutical composition comprising as an active ingredient at least one selected from the group consisting of an Akkermansia muciniphila strain cultured in a mucin-free medium, an endoplasmic reticulum derived therefrom, a culture thereof, a concentrate of the culture, a dry matter of the culture, and an extract of the culture.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the metabolic disease is one selected from the group consisting of hyperlipidemia, fatty liver, obesity, diabetes, arteriosclerosis, and hypertension.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the composition further comprises a carrier, an excipient, or a diluent, in addition to the active ingredient.

### Claim 13

A method of preventing or improving a metabolic disease, comprising a step of:
administering a health functional food composition comprising as an active ingredient at least one selected from the group consisting of an Akkermansia muciniphila strain cultured in a mucin-free medium, an endoplasmic reticulum derived therefrom, a culture thereof, a concentrate of the culture, a dry matter of the culture, and an extract of the culture.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the metabolic disease is one selected from the group consisting of hyperlipidemia, fatty liver, obesity, diabetes, arteriosclerosis, and hypertension.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the composition further comprises in addition to the active ingredient at least one selected from a nutrient, a vitamin, an electrolyte, a flavoring agent, a coloring agent, an enhancer, a pectic acid and a salt thereof, an alginic acid and a salt thereof, an organic acid, a protective colloid thickening agent, a pH-adjusting agent, a stabilizer, a preservative, glycerin, an alcohol, and a carbonating agent used for carbonated drinks.

### Claim 16

A method of preventing or improving a metabolic disease, comprising a step of:
administering a feed additive composition comprising as an active ingredient at least one selected from the group consisting of an Akkermansia muciniphila strain cultured in a mucin-free medium, an endoplasmic reticulum derived therefrom, a culture thereof, a concentrate of the culture, a dry matter of the culture, and an extract of the culture.
